Resources for use
with your patients

This website is intended for healthcare professionals outside of the US and UK

ELAPRASE® administration

Several resources are available to provide information about how to administer ELAPRASE

Click here to view the Prescribing Information or Safety Information

The 6-minute walk test tracker:

The 6-minute walk test (6-MWT) is one of the recommended assessments to monitor the disease progression of patients with Hunter syndrome, and also their response to therapy.3 The 6-MWT is a self-paced assessment that reflects the pace and ability to carry out daily physical activities.4 A 6-MWT tracker worksheet is available to download:

Download now

A diagnosis of Hunter syndrome can have a large impact for both patients and their caregivers. It is important to explain to them about the disease, the cause of the disease, and the common therapies used to treat both the symptoms and cause of Hunter syndrome. Click on the links below to download information to give to your patients to help explain their disease.

What is Hunter syndrome?

Hunter syndrome is one member of a group of genetic metabolic disorders called mucopolysaccharidoses and is often referred to as mucopolysaccharidosis II (MPS II). These metabolic disorders are caused by inefficiency or absence of enzymes which break down and recycle glycosaminoglycans (or GAGs).1

Download now

Who is involved in the management of Hunter Syndrome?

Hunter syndrome patients can be affected by a wide variety of symptoms in many different parts of the body. Therefore physicians from a range of medical specialities and supportive services may be involved in their treatment as part of multidisciplinary team.2

Download now


  1. Muenzer J. Rjeumatology. 2011;50(5):4-12.

  2. Muenzer J, Beck M, Eng C et al. Pediatrics. 2009;124(6):e1228-e1239.

  3. Scarpa M, Almassy Z, Beck M et al. Orphanet J Rare Dis. 2011;6:72.

  4. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med. 2002;166(1):111–117.